Curr Opin Gastroenterol. 2022 Jul 1;38(4):321-327.doi: 10.1097/MOG.0000000000000855.

Florence-Damilola Odufalu ¹, Aiya Aboubakr ², Adjoa Anyane-Yeboa ³

Author information

¹Division of GI & Liver Disease, Department of Medicine, Keck School of Medicine of USC, Los Angeles, California.

²Department of Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, New York.

³Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Abstract

Abstract

Purpose of review: The incidence of inflammatory bowel disease (IBD) is increasing in minority groups across the USA. There are racial and ethnic disparities in IBD care and outcomes that are rooted in historical injustice and inequities in the social determinants of health.

Recent findings: Current literature has identified racial, ethnic and sociodemographic disparities in therapeutics and outcomes for IBD, including disease severity, morbidity and mortality.

Summary: Strategies to achieve equity in IBD include tackling structural racism as a driver of health disparities and making actionable changes against multilevel barriers to care.